Latin American pharma Biotoscana confirms in sale talks - filing

Knight Therapeutics

08/10/2019 14:31

SAO PAULO, Oct 8 (Reuters) - Latin American pharmaceutical
company Biotoscana Investments  GBIO33.SA  confirmed that its
shareholders were in talks with investors about a sale,
according to a securities filing on Monday.
    "The company's shareholders are in talks with investors, but
have not yet taken a decision on a transaction", it said, adding
there would be a mandatory offering to all shareholders if the
company's control changed.
    Reuters reported on Monday that Brazilian pharmaceutical
firm Eurofarma and Canada's Knight Therapeutics  GUD.TO  were in
talks with Biotoscana's shareholders, led by private equity fund
Advent International.  urn:newsml:reuters.com:*:nL2N26S0ID

 (Reporting by Tatiana Bautzer;
Editing by Edmund Blair)
 ((tatiana.bautzer@tr.com; Tel: +55-11-5644-7756; Mob:
+55-119-4210-4173; Reuters Messaging:
tatiana.bautzer.thomsonreuters.com@reuters.net))